The golden age of pharmaceutical innovation has come! The two short boards still need to be strengthened

At present, under the resonance of policies, market access, financing channels, talents and other factors, new technologies, new demands and new tracks are emerging intensively in the pharmaceutical and biological industry.
industry believes that innovative drugs are ushering in the golden age of time, land, people and, but the two short boards still need to be strengthened.
, a series of good policies in recent years have pointed to encouraging the development of innovative pharmaceutical industries, such as the reform of the drug review system, the accession of Chinese drug regulatory agencies to ICH, and the acceleration of the approval of innovative drugs.
under the power of these policies, the development of generic drugs has been suppressed to a certain amount, with innovative drugs as the main line of the fine molecular industry market demand is gradually activated, forcing pharmaceutical companies to transition and upgrade in the direction of innovation.
, the domestic CRO technology level and quality system continue to be in line with international standards, the global pharmaceutical outsourcing industry chain is also constantly transferred to the domestic.
, according to Frost Sullivan, the market size of our CRO industry has risen rapidly from $2.1 billion in 2014 to $5.9 billion in 2018, with CAGR reaching 29%.
addition to introducing policies to encourage drug research and development, market access, financing channels, talent and other aspects are also good for the development of innovative pharmaceutical industry.
market access, which is also changing in terms of market access.
although the current health insurance market has not yet formed a fully mature program, but from the annual changes in the health care negotiation strategy, recruitment policies, it is not difficult to see the domestic market access is continuing to explore.
, because the pharmaceutical innovation industry has the characteristics of high-tech intensive, high input, long cycle, high output and high risk, the financing environment for pharmaceutical innovation in China has been optimized in recent years.
channels of financing have been widened to allow unprofitable innovative pharmaceutical companies to list on the Mainland's Kotson board and the Hong Kong Stock Exchange.
the present, domestic pharmaceutical companies that focus on innovative drug research and development, have large capital needs, have not yet made a profit or are in a loss-making state, can use the science and technology board, GEM, HONG KONG Stock Exchange to finance.
, the number of college graduates in China exceeds 7 million each year, and the number of graduate students enrolled in Shubo exceeds 600,000, with a large reserve of professionals.
Addition, the return of high-quality overseas students has accelerated in recent years, according to statistics, from 1978 to the end of 2018, all kinds of overseas students reached a cumulative total of 5.8571 million people, of whom 3.6514 million chose to return home after completing their studies to develop.
china's international influence gradually increased, the number of returning students is expected to further expand, will effectively support the development of science and technology and industry.
can see that the pharmaceutical innovation industry is ushering in a golden period of development.
but at the same time to see the business climate, the industry believes that there are still two short boards still need to be strengthened, one is basic research, the other is the transformation capacity.
industry believes that a mature pharmaceutical innovation environment needs to be composed of infrastructure, research and development systems, policy support and market access.
these two short boards need to be complemented by strengthening basic research, basic education and basic scientific research, as well as improving their transformational capabilities.
the author learned that at present, China is taking the transformation system of biomedicine, which is linked by industry, science and research, and is centered on enterprises, and constantly improving the level of transformation.
, such as Zhuhai, focuses on supporting the innovation and development of new products and technologies in the field of biomedicine, strengthening the construction of public service platforms, supporting the breakthrough of key technologies in the field of biomedicine, and improving the independent innovation capability of the industry.
To promote the efficient allocation and integration of scientific and technological achievements with local industrial resources, to promote the transformation of international cooperation and innovation projects, major national scientific and technological projects and achievements in the field of biomedicine, and to deepen cooperation between Shanghai and Fengxian District in improving the basic research and development, functional transformation and public service platform of Fengxian biopharmaceutical industry.